Viromed Medical AG has successfully completed a capital increase announced earlier today, placing 450,000 new registered no-par value shares at EUR 4.50 per share. The gross proceeds of approximately EUR 2 million will be used to finance the company's working capital, according to the press release distributed via NEWMEDIAWIRE.
The capital increase was executed by partially utilizing the Authorized Capital 2025 and with the exclusion of shareholders' subscription rights. Subject to registration in the commercial register, the share capital will rise from EUR 21,250,000 to EUR 21,700,000. The move bolsters Viromed's financial flexibility as it pursues growth in the medical technology sector.
Viromed Medical AG specializes in the development, manufacture and distribution of medical products, with a focus on innovative cold plasma technology for medical applications through its wholly owned subsidiary, Viromed Medical GmbH. The company has been listed on the stock exchange since October 2022 and serves a broad customer base in the DACH region and beyond. Further details about the company are available at www.viromed-medical-ag.de.
The completion of the capital increase is significant because it provides Viromed with immediate liquidity to support its operating business and strategic objectives. The company aims to further advance the use of cold plasma technology in medicine and realize corresponding growth potential. By securing additional working capital, Viromed can continue investing in the development and distribution of its innovative products without the delay that might accompany alternative financing methods. The exclusion of subscription rights, while potentially dilutive to existing shareholders, allowed for a swift placement of shares, which may be seen as a sign of confidence by investors in the company's prospects. The capital increase also demonstrates Viromed's ability to access public markets, which is crucial for a growth-oriented medical technology firm. As the company continues to expand its customer base and promote cold plasma technology, the additional funds will help sustain its operations and support long-term value creation. The original release can be viewed on www.newmediawire.com.
